|11 May 2017||Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement|
|DUBLIN, Ireland, May 11, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following.
In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the "Irish Takeover Rules"), Nexvet confirms that as at close of business on May 10, 2017 its issued share capital comprised 11,916,712 ordinary shares of $0.125 each (the “Ordinary Shares”). The Ordinary Shares are admitted to trading on NASDAQ under the ticker symbol NVET. The International ... |
|11 May 2017||Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2017|
|DUBLIN, Ireland, May 11, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and nine month periods ended March 31, 2017.
In April 2017, entered into a Transaction Agreement for Zoetis to acquire all Nexvet shares for $6.72 per ordinary share in cash, valuing Nexvet at approximately $85 million
Advanced key clinical programs and implemented a cost reduction program
Signed a licensing agreement with Pfizer ... |
|13 April 2017||Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals|
|Purchase price of US$6.72 per share, or approximately US$85 million
Acquisition to strengthen Zoetis’ pipeline in companion animal
therapeutics for chronic pain, a global area estimated at US$400
PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--Apr. 13, 2017--
Inc. (NYSE:ZTS) and Nexvet
Biopharma plc (Nasdaq:NVET) today announced an agreement in which
|22 February 2017||Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference|
|DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6th at 1:20PM ET.
Dr. Heffernan will discuss Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, consisting of ranevetmab and frunevetmab; the significant progress made at the Company’s manufac... |
|10 February 2017||Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017|
|DUBLIN, Ireland, Feb. 10, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and six month periods ended December 31, 2016.
Initiated pivotal field efficacy and safety studies of frunevetmab, the Company’s anti-nerve growth factor monoclonal antibody (anti-NGF mAb) in development for the control of pain associated with osteoarthritis in cats
Entered into a research collaboration with Genentech